Physician profile
William Wolf
NPI 1104087840
$77,748.85
in general payments reported to CMS, 2019-2025
37 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,579 · 2021: $12K · 2022: $16K · 2023: $16K · 2024: $9,672 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $6,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,240.00 |
| Food and Beverage | $6,355.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56,374.31 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $10,094.34 | 2019-2025 | Farxiga, Wainua, Bevespi Aerosphere |
| Medtronic, INC. | $3,318.24 | 2021-2025 | Onyx Frontier, Octopus, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $1,470.38 | 2019-2025 | |
| Pfizer INC. | $896.02 | 2019-2025 | |
| Amgen INC. | $851.96 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $821.74 | 2020-2025 | General - Therapies, Avvigo Guidance System, Watchman Access System |
| Abiomed | $644.83 | 2019-2025 | Impella |
| Abbott Laboratories | $502.32 | 2021-2025 | Ultreon, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $263.13 | 2019-2025 | Camzyos, Eliquis |
| Opsens INC. | $256.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.94 | 2019-2024 | Jardiance |
| Atricure, INC. | $204.62 | 2022-2025 | Synergy Ablation System |
| Biosense Webster, INC. | $201.54 | 2024 | Carto 3 |
| Amarin Pharma, INC. | $183.95 | 2019-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.